SynthesisJournal of endocrinological investigation2019
Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis.
Synthesis in Journal of endocrinological investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Efficacy of acceptance and commitment therapy for people with type 2 diabetes: Systematic review and meta-analysis.Journal of diabetes investigation · 2022Pooled it
- Efficacy of a meal sequence in patients with type 2 diabetes: a systematic review and meta-analysis.BMJ open diabetes research & care · 2022Pooled it
- GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs.Cardiovascular diabetology · 2021Pooled it
- HbADiabetes care · 2021Pooled it
- 5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine.Diabetes, obesity & metabolism · 2024 · on this mapTrial
- Glycemic trends following hypoglossal nerve stimulation in patients with obstructive sleep apnea and type 2 diabetes.Sleep & breathing = Schlaf & Atmung · 2026Article
- GLP-1 receptor agonists as multisystem therapies: from glycemic control to cardiorenal, neuroimmune, and metabolic disease.Diabetology & metabolic syndrome · 2026Review
- Article
- The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes.Current atherosclerosis reports · 2025Review
- The Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- The Interconnected Complexity of Diabetes and Depression.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
- Metabolite Profiles of Plant-Based Diets and Cardiometabolic Risk in the Mediators of Atherosclerosis in South Asians Living in America Study.The Journal of nutrition · 2024Article
- [Screening, risk stratification and CT imaging for assessment of coronary artery disease].Radiologie (Heidelberg, Germany) · 2024Article
- Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- Change in cardiometabolic risk factors in a pilot safety-net plant-based lifestyle medicine program.Frontiers in nutrition · 2023Article
- Article
- Exenatide Once Weekly for Management of Type 2 Diabetes: A Review.Clinical pharmacology : advances and applications · 2022Review
- Lumbar spine bone mineral density and trabecular bone score-adjusted FRAX, but not FRAX without bone mineral density, identify subclinical carotid atherosclerosis.Journal of endocrinological investigation · 2021Article
- Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study.Cardiovascular diabetology · 2021Observational
- Calcium-Sensing Receptor Participates in High Glucose-Induced EndMT in Primary Human Aortic Endothelial Cells.Frontiers in physiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe did a meta-analysis with meta-regression to evaluate the relationship between hemoglobin A1c (A1C) reduction and the primary CV outcome of cardiovascular outcome trials (CVOTs).
methodsWe used a random effects meta-analysis of the 12 CVOTs to quantify the effect of A1C reduction on major cardiovascular events (MACE) risk by stratifying the difference in achieved A1C (drug vs placebo) in three strata: A1c < 0.3%, A1c ≥ 0.3% and < 0.5%, and A1c ≥ 0.5%.
resultsWe found a relation between the reduction in achieved A1C and the hazard ratio reduction for MACE (P = 0.002), explaining almost all (94.1%) the between-study variances: lowering A1C by 0.5% conferred a significant HRR of 20% (95% CI 4-33%) for MACE.
conclusionsBlood glucose reduction may play a more important role than previously thought in reducing the risk of MACE during treatment with the newer glucose-lowering drugs, including peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.